By John Stanford The Federal Trade Commission just announced plans to “take an aggressive approach to tackling anticompetitive pharmaceutical mergers.” Kelly Slaughter, the acting head of the agency, recently blamed the “high volume of pharmaceutical mergers in recent years … [for] skyrocketing drug prices.” Not only are her actions without merit, but they also imperil […]
The post What M&A Critics Don’t Understand About Drug Innovation first appeared on The Madison Times.
